EA202090303A2 - COMPOSITIONS OF ANTIBODIES FOR TREATMENT OF TUMORS - Google Patents

COMPOSITIONS OF ANTIBODIES FOR TREATMENT OF TUMORS

Info

Publication number
EA202090303A2
EA202090303A2 EA202090303A EA202090303A EA202090303A2 EA 202090303 A2 EA202090303 A2 EA 202090303A2 EA 202090303 A EA202090303 A EA 202090303A EA 202090303 A EA202090303 A EA 202090303A EA 202090303 A2 EA202090303 A2 EA 202090303A2
Authority
EA
Eurasian Patent Office
Prior art keywords
antigen binding
bispecific antibodies
certain embodiments
present
antibodies
Prior art date
Application number
EA202090303A
Other languages
Russian (ru)
Other versions
EA202090303A3 (en
Inventor
Самьюэл Дэвис
Эрик Смит
Бинду Варгиз
Джессика Р. Киршнер
Гэвин ТЕРСТОН
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA202090303A2 publication Critical patent/EA202090303A2/en
Publication of EA202090303A3 publication Critical patent/EA202090303A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В настоящем изобретении предложены биспецифические антитела, которые связываются с CD3 и опухолевыми антигенами, а также способы их применения. В соответствии с определенными вариантами реализации биспецифические антитела согласно изобретению демонстрируют сниженные эффекторные функции и имеют уникальный профиль связывания в отношении Fc-рецепторов. Биспецифические антитела сконструированы так, чтобы эффективно индуцировать опосредованное Т-клетками уничтожение опухолевых клеток. В соответствии с определенными вариантами реализации в настоящем изобретении предложены биспецифические антигенсвязывающие молекулы, содержащие первый антигенсвязывающий домен, который специфически связывает человеческий CD3, вторую антигенсвязывающую молекулу, которая специфически связывает человеческий CD20, и Fc-домен, который связывает Fc-рецепторы со специфическим профилем связывания. В определенных вариантах реализации изобретения биспецифические антигенсвязывающие молекулы согласно настоящему изобретению способны ингибировать рост В-клеточных или меланомных опухолей, экспрессирующих CD20. Биспецифические антитела согласно изобретению применимы для лечения различных видов рака, а также других связанных с CD20 заболеваний и нарушений.The present invention provides bispecific antibodies that bind to CD3 and tumor antigens, as well as methods of using them. In accordance with certain embodiments, bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile for Fc receptors. Bispecific antibodies are designed to effectively induce T cell mediated tumor cell killing. In accordance with certain embodiments, the present invention provides bispecific antigen binding molecules comprising a first antigen binding domain that specifically binds human CD3, a second antigen binding molecule that specifically binds human CD20, and an Fc domain that binds Fc receptors with a specific binding profile. In certain embodiments, the bispecific antigen binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20. The bispecific antibodies of the invention are useful in the treatment of various cancers as well as other CD20-related diseases and disorders.

EA202090303A 2014-08-05 2015-03-18 ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS EA202090303A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462033460P 2014-08-05 2014-08-05

Publications (2)

Publication Number Publication Date
EA202090303A2 true EA202090303A2 (en) 2020-05-31
EA202090303A3 EA202090303A3 (en) 2020-08-31

Family

ID=70847642

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090303A EA202090303A3 (en) 2014-08-05 2015-03-18 ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS

Country Status (1)

Country Link
EA (1) EA202090303A3 (en)

Also Published As

Publication number Publication date
EA202090303A3 (en) 2020-08-31

Similar Documents

Publication Publication Date Title
EA201691858A1 (en) ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS
JOP20200237A1 (en) Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
CY1124634T1 (en) PD-1 AND LAG-3 BINDING MOLECULES AND METHODS OF USING THEM
EA201890368A1 (en) ANTIBODIES AGAINST PSMA, BISPECIFIC ANTIGENSELATING MOLECULES THAT BIND PSMA AND CD3 AND THEIR APPLICATION
EA201890785A1 (en) OPTIMIZED BISPECIFIC ANTI-CD3 ANTIBODIES AND THEIR APPLICATION
EA202191580A1 (en) SPECIFIC ANTI-CD28 X ANTI-CD22 ANTI-BODIES AND THEIR APPLICATION
MX2021013681A (en) Lag-3-binding molecules and methods of use thereof.
EA201892362A1 (en) AGONISTIC ANTIBODIES THAT ARE BINDING HUMAN CD40, AND THEIR OPTIONS
MX2023003418A (en) Multispecific antigen-binding molecules and uses thereof.
EA201491686A1 (en) MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND THEIR APPLICATIONS
EA201790060A1 (en) BISPECIFIC CD33- and CD3-BINDING PROTEINS
MX2017001599A (en) Novel antibodies and uses thereof.
EA201690167A1 (en) HUMANIZED OR CHEMICAL ANTIBODIES TO CD3
EA201790719A1 (en) BISPECIFIC MONOVALENT DIATELS, WHICH ARE CAPABLE TO BIND CD19 AND CD3, AND THEIR APPLICATION THEREOF
EA201792581A1 (en) METHODS OF APPLICATION OF BISPECIFIC CD33- and CD3-BINDING PROTEINS
MX2021003756A (en) Pharmaceutical compositions comprising bispecific anti-cd37 antibodies.
EA202090303A2 (en) COMPOSITIONS OF ANTIBODIES FOR TREATMENT OF TUMORS
AR099798A1 (en) METHODS AND COMPOSITIONS OF ANTIBODIES FOR TUMOR TREATMENT
EA202092279A1 (en) ANTIBODIES TO MICA AND / OR MICB AND THEIR APPLICATION
EA201991227A1 (en) ANTIBODIES AGAINST CD3, SPECIFIC ANTIGEN-BINDING MOLECULES, WHICH BIND TO AND CD3 AND CD20
EA202090579A1 (en) PD-1-BINDING MOLECULES AND METHODS OF THEIR APPLICATION